



Correction to: Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA

Kate McKeage¹ · Katherine A. Lyseng-Williamson¹

Published online: 16 November 2018
© Springer Nature 2018

Correction to:

Drugs & Therapy Perspectives (2018) 34(10):451–456
<https://doi.org/10.1007/s40267-018-0551-x>

The article Fostamatinib in chronic immune thrombocytopenia: a profile of its use in the USA, was originally published Online First without open access. After publication in volume 34, issue 10, pages 451–456, Rigel Pharmaceuticals, Inc. requested that the article be Open Choice to make the article an open access publication. Post-publication open access was funded by Rigel Pharmaceuticals, Inc. The article is forthwith distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<http://creativecommons.org/licenses/by-nc/4.0/>), which

permits any noncommercial use, duplication, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license and indicate if changes were made.

The original article has been corrected.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<http://creativecommons.org/licenses/by/4.0/>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

The original article can be found online at <https://doi.org/10.1007/s40267-018-0551-x>.

✉ Katherine A. Lyseng-Williamson
dtp@adis.com

¹ Springer, Private Bag 65901, Mairangi Bay, Auckland 0754, New Zealand